Urovant Sciences (Urovant Sciences) Total Payout Yield % : 0.00 (As of May. 08, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Urovant Sciences Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Urovant Sciences's current Total Payout Yield % is 0.00%.

Urovant Sciences Total Payout Yield % Historical Data

The historical data trend for Urovant Sciences's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urovant Sciences Total Payout Yield % Chart

Urovant Sciences Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Total Payout Yield %

-43.62

Urovant Sciences Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Total Payout Yield %	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Urovant Sciences's Total Payout Yield %

For the Biotechnology subindustry, Urovant Sciences's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Urovant Sciences's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Urovant Sciences's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Urovant Sciences's Total Payout Yield % falls into.

Urovant Sciences Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Urovant Sciences's Total Payout Yield % for the fiscal year that ended in Mar. 2020 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	0	+	0)	/	282.457466
	=	0.00%

Urovant Sciences's annualized Total Payout Yield % for the quarter that ended in Dec. 2020 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0	+	0)	*	4	/	524.77342
	=	0.00%

Urovant Sciences Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Urovant Sciences Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Urovant Sciences's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Urovant Sciences (Urovant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Urovant Sciences Ltd (NAS:UROV) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11-12 St. Jamesâ€™s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB

Website

https://www.urovant.com

Urovant Sciences Ltd is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's pipeline products include Overactive Bladder (OAB), OAB in Men with Benign Prostatic Hyperplasia (BPH), and IBS-Associated Pain.

Executives

Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Sef Kurstjens	director	C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
James M. Hindman	director	2525 DUPONT DRIVE, IRVINE CA 92612
Walt Johnston	officer: SVP, Commercial, USI	UROVANT SCIENCES LTD. 5281 CALIFORNIA AVE SUITE 100 IRVINE CA 92617
Haag-molkenteller Cornelia	officer: CMO/Urovant Sciences, Inc.	C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617
Bryan E. Smith	officer: GC/Urovant Sciences, Inc.	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Christine Ocampo	officer: PAO;CAO/Urovant Sciences, Inc	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Ajay Bansal	officer: PFO;CFO/Urovant Sciences, Inc.	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Robinson James A. Jr.	director, officer: PEO;CEO/Urovant Sciences, Inc.	852 WINTER STREET, WALTHAM MA 02451
Sumitomo Chemical Co., Ltd.	other: See Footnote (1)	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Sumitovant Biopharma Ltd.	10 percent owner	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd	other: See Footnote (1)	6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Keith Katkin	director, officer: PEO;CEO/Urovant Sciences, Inc.	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Shigeyuki Nishinaka	director	5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617